Neil Murdock Pfizer Inc PFE-N HOLD Jan 13, 2003

A few weeks ago, they reported great earnings, but shares were down because the Covid vaccine drove earnings. Today, shares are down another 5-6%. She added shares a few weeks ago, but is holding now.

Valuation of 10x forward PE. People are missing that they took the windfall from Covid and have redeployed it into acquiring assets, mainly in oncology drugs. We should start to see the growth from that spending in the next couple of years. Could get them to start growing again. Meanwhile, vaccines are still a core position. Yield is 6.5%.

Downside support, upside potential, a bit of earnings growth, low valuation.

Despite buying a bunch of mega-companies, it remains cheaper than 30 years ago. But it has totally failed to deliver shareholder value. The dividend is safe. 

Acquisitions in oncology weren't enough for the stock. A long-term play. Slightly disappointing on the year, but oncology segment will continue to do well going forward.

If he's right about a correction in 2025, money managers will rotate into defensive areas like staples, utilities, healthcare and REITs. Their chart was in a big downtrend in recent years. PFE's chart has a double bottom this year. Relative strength is moving up. Also, volumes has popped around $25 (trough). The risk/reward is good. You're paid 6.5% to wait, too. $25 is big technical support.

It's too low to sell. Collect the dividend and see if we get good news about the Seagen acquisition.

Market's been tough on it. Investing $2B a year on R&D, made some acquisitions. Lots in the pipeline is up in the air. Stock will pop eventually back to its historical $40-45, and then he'll probably cash in. In his income fund, with the yield at 6%.

It has over paid for some M&A. It is a deep value play but needs a catalyst. It has had some management change but recovery is not part of their investment style. They sold about a year and a half ago.

It reports Tuesday. Their anti-cancer drugs still haven't broken up to justify the cost of acquiring them. Good news would pop shares up. Little downside now.

It's cheap, but for a reason. Sees no growth, despite a big acquisition. Consider Merck or Amgen for perhaps more growth.